



# Antimicrobial Stewardship in Australian Health Care

Published by the Australian Commission on Safety and Quality in Health Care

Level 5, 255 Elizabeth Street, Sydney NSW 2000

Phone: (02) 9126 3600

Email: [mail@safetyandquality.gov.au](mailto:mail@safetyandquality.gov.au)

Website: [www.safetyandquality.gov.au](http://www.safetyandquality.gov.au)

ISBN: 978-1-922563-99-6

© Australian Commission on Safety and Quality in Health Care 2022

All material and work produced by the Australian Commission on Safety and Quality in Health Care (the Commission) is protected by copyright. The Commission reserves the right to set out the terms and conditions for the use of such material.

As far as practicable, material for which the copyright is owned by a third party will be clearly labelled. The Commission has made all reasonable efforts to ensure that this material has been reproduced in this publication with the full consent of the copyright owners.

With the exception of any material protected by a trademark, any content provided by third parties and where otherwise noted, all material presented in this publication is licensed under a Creative Commons Attribution–NonCommercial–NoDerivatives 4.0 International licence.

Enquiries about the licence and any use of this publication are welcome and can be sent to [communications@safetyandquality.gov.au](mailto:communications@safetyandquality.gov.au).

The Commission's preference is that you attribute this publication (and any material sourced from it) using the following citation:

Australian Commission on Safety and Quality in Health Care. *Antimicrobial Stewardship in Australian Health Care*. Sydney: ACSQHC; 2023

#### **Disclaimer**

The content of this document is published in good faith by the Commission for information purposes. The document is not intended to provide guidance on particular healthcare choices. You should contact your healthcare provider for information or advice on particular healthcare choices.

This document includes the views or recommendations of its authors and third parties. Publication of this document by the Commission does not necessarily reflect the views of the Commission or indicate a commitment to a particular course of action. The Commission does not accept any legal liability for any injury, loss or damage incurred by the use of, or reliance on, this document.

# Acknowledgements

Antimicrobial Stewardship in Australian Health Care 2018 has been developed through the contributions of many individuals and organisations who are committed to improving antimicrobial use in hospitals and reducing the risk of harm to patients from inappropriate antimicrobial prescribing. The Australian Commission on Safety and Quality in Health Care (the Commission) wishes to thank the following contributing authors for their expertise and time given to the writing of this publication:

- Dr Tara Anderson – Infectious Diseases Physician and Clinical Microbiologist, Medical Advisor Infection Prevention and Control, Royal Hobart Hospital, and Specialist Medical Advisor Tasmanian Infection Prevention and Control Unit (particularly Chapter 2)
- Associate Professor Noleen Bennett – National Centre for Antimicrobial Stewardship, Victorian Healthcare Associated Infection Surveillance System (VICNISS) Co-ordinating Centre (particularly Chapter 12 and 16)
- Dr Penelope Bryant - Paediatric Infectious Diseases Physician and General Paediatrician, the Royal Children's Hospital (particularly Chapter 14)
- Associate Professor Kirsty Busing – National Centre for Antimicrobial Stewardship (particularly Chapters 3, 6, 17 and 19)
- Clinical Associate Professor Susan Benson – Path West Laboratory Medicine, Western Australian Department of Health and University of Western Australia (particularly Chapter 9)
- Dr Celia Cooper – SA Pathology, SA Health (particularly Chapters 5, 8 and 14)
- Dr Menino Cotta – Research Fellow University of Queensland (particularly Chapter 19)
- Dr Jonathan Dartnell – NPS MedicineWise (particularly Chapters 7, 10 and 13)
- Ms Margaret Duguid – Australian Commission on Safety and Quality in Health Care (contribution to Chapters 1-12)
- Conjoint Associate Professor John Ferguson – Hunter New England Local Health District (particularly Chapter 9)
- Ms Fiona Gotterson – Australian Commission on Safety and Quality in Health Care (particularly Chapters 3, 5 and 12)
- Dr Rod James, Director of Clinical Services, National Centre for Antimicrobial Stewardship (particularly Chapter 17)
- Dr David Kong – Ballarat Health Services and Centre for Medicine Use and Safety, Monash University (particularly Chapter 11 and 16)
- Dr Jolene CJ Lim – Australasian College for Emergency Medicine (particularly Chapter 16)
- Associate Professor David Looke – Infectious Diseases Physician and Clinical Microbiologist, Princess Alexandra Hospital; and Associate Professor, University of Queensland (particularly Chapter 6 and 18)
- Dr Geraldine Moses – Consultant Pharmacist to the Australian Dental Association (ADA); and Consultant Clinical Pharmacist Mater Health Services Brisbane (particularly Chapter 18)
- Professor Graeme Nimmo – Pathology Queensland, Queensland Health (particularly Chapter 9)
- Ms Bhavini Patel – Executive Director Medicines Management: Research, Transformation and Change, Top End Health (particularly Chapter 15)
- Ms Lisa Pulver – NPS MedicineWise (particularly Chapters 7, 10 and 13)
- Dr Kate Raymond – Principal Dental Advisor, Oral Health Services NT (particularly Chapter 18)
- Professor Debra Rowett – NPS MedicineWise (particularly Chapters 7, 10 and 13)
- Dr Thomas R Schulz, Infectious Diseases and General Physician (Royal Melbourne Hospital) (particularly Chapter 17)
- Professor Karin Thursky – National Centre for Antimicrobial Stewardship (particularly Chapter 4)
- Professor John Turnidge AO – Australian Commission on Safety and Quality in Health Care (particularly Chapters 1, 3, and 18)
- Dr Helen Van Gessel – Albany Hospital (particularly Chapter 2)
- Emeritus Professor Laurence Walsh – Professor of Dental Science, The University of Queensland School of Dentistry, UQ Oral Health Centre (particularly Chapter 18)
- Dr Morgyn Warner – SA Pathology, SA Health (particularly Chapter 1)
- Dr Jeanie Yoo – NPS MedicineWise (particularly Chapters 10 and 13).

The Commission also wishes to extend its thanks to the following individuals who have provided their considered advice in the review of the content of this book:

- Dr Lorraine Anderson – Medical Director Kimberly Aboriginal Medical Services (particularly Chapter 15)
- Dr Minyon Avent, Advanced Pharmacist, QLD Statewide AMS program (particularly Chapter 17)
- Dr Sean Beggs, Paediatrician – The Royal Hobart Hospital (particularly Chapter 14)
- Dr Philippa Binns – public health physician and general practitioner
- Ms Jaclyn Bishop, PhD Fellow National Centre for Antimicrobial Stewardship (NCAS), Peter Doherty Institute for Infection and Immunity, VIC (particularly Chapter 17)
- Associate Professor Asha Bowen – Head of Skin Health at the Wesfarmers Centre of Vaccines and Infectious Diseases, based at Telethon Kids Institute (particularly Chapter 15)
- Ms Lisa Campbell – Infection Control Specialist, Bolton Clarke (particularly Chapter 16)
- Dr Megan Campbell – Centre for Aboriginal Health NSW (particularly Chapter 15)
- Ms Lydia Che, AMS Pharmacist, Tweed Byron Network, NNSW LHD, NSW (particularly Chapter 17)
- Ms Amy Chen – AMS Pharmacist, Monash Children’s Hospital (particularly Chapter 14)
- Ms Lisa Course – Sunshine Coast Hospital and Health Service (particularly Chapter 16)
- Dr Stuart Crisp – Paediatrician, Orange, NSW (particularly Chapter 14)
- Professor Chris Del Mar – Centre for Research in Evidence-Based Practice, Bond University
- Mr Stuart Donohoe – Infection Control Specialist, Bolton Clarke (particularly Chapter 16)
- Dr Kylie Easton – NPS MedicineWise
- Ms Gauri Godbole – Team Leader Pharmacist in aged care and mental health Gosford Hospital, NSW (particularly Chapter 16)
- Ms Zoy Goff – AMS Pharmacist, Perth Children’s Hospital (particularly Chapter 14)
- Associate Professor Thomas Gottlieb - Senior Staff Specialist, Microbiology & Infectious Diseases, Concord Hospital
- Dr Jenny Gowan – Consultant clinical pharmacist (particularly Chapter 16)
- Ms Nicolette Graham – AMS Pharmacist, Queensland Children’s Hospital (particularly Chapter 14)
- Dr Malene Hansen – Centre for Research in Evidence-Based Practice, Bond University
- Dr Helen Harris, Deputy Executive Director of Medical Services at the Royal Hobart Hospital (particularly Chapter 17)
- Ms Dorothy Harrison – consumer representative reviewer
- Mr Ged Hawthorn, Senior Clinical Pharmacist, Orange Health Service, NSW (particularly Chapter 17)
- Ms Aine Heaney – NPS MedicineWise
- Dr Adam Irwin – conjoint Senior Lecturer and academic lead for Paediatric Infectious Disease at Children’s Health Queensland and the University of Queensland (particularly Chapter 14)
- Dr Sonja Janson – Infectious diseases physician Royal Darwin Hospital, Antimicrobial Stewardship lead Top End, Big Rivers, East Arnhem Regions of Northern Territory (particularly Chapter 20)
- Katie Jodrell– AMS Pharmacist, St John of God (particularly Chapter 19)
- Bettina Kirk – AMS Pharmacist, Icon group (particularly Chapter 19)
- Mr Tony Lai – AMS Pharmacist, The Children’s Hospital at Westmead (particularly Chapter 14 and 20)
- Ms Amy Legg – Top End Health Service Antimicrobial Stewardship Pharmacist (particularly Chapter 15)
- Dr Lin-li Lim – Infectious Diseases specialist undertaking sabbatical with the Aged Care Quality and Safety Commission (ACSQC) (particularly Chapter 16)
- Christine Lo – AMS Pharmacist, Cabrini Health, Vic (particularly Chapter 19)
- Ms Elaine Lum – Institute of Health and Biomedical Innovation, Faculty of Health, Queensland University of Technology
- Dr Carolyn Leerdam – Paediatrician, Canberra Hospital (particularly Chapter 14)
- Professor Jennifer May – Member, ACSQHC Primary Care Committee (particularly Chapter 13)
- Associate Professor Kate McCarthy – Infectious Diseases Physician, Royal Brisbane and Women’s Hospital (particularly Chapter 20)
- Dr Amanda McCullough – Centre for Research in Evidence-Based Practice, Bond University

- Dr Brendan McMullan – Paediatric ID Specialist, Sydney Children’s Hospital, Randwick (particularly Chapter 14)
- Martina Mooyman– AMS Pharmacist, Wesley Hospital (particularly Chapter 19)
- Prof Mary O'Reilly – Infectious Diseases specialist, Cabrini Health, Vic (particularly Chapter 19)
- Nurdan Ozkan – AMS Pharmacist, Sydney Adventist Hospital (particularly Chapter 19)
- Ms Funda Ozneç – Quality & Clinical Excellence Manager, Villa Maria Catholic Homes (particularly Chapter 16)
- Ms Carly Pauw – Senior Pharmacist, Hospital in the Home, Integrated & Community Health WSLHD (particularly Chapter 20)
- Ms Katie Pennington – Continuous Quality Improvement Officer Puntukurnu Aboriginal Medical Services (particularly Chapter 15)
- Dr Geoffrey Playford – Director, Infection Management Services, Princess Alexandra Hospital
- Dr James Pollard – ID Physician and Clinical Director Community Care, Cabrini Health, Vic; and President, HITH Society of Australasia (particularly Chapter 20)
- Ms Amber Polles – KP Health (particularly Chapter 13 and 14)
- Dr Deena Parbhoo – AMS Paediatrician, Monash Children’s Hospital (particularly Chapter 14)
- Adjunct Associate Professor Debbie Rigby – Consultant clinical pharmacist (particularly Chapter 16)
- Professor Jason Roberts – Acting Director, University of Queensland Centre for Clinical Research, The University of Queensland and Interim Director, Herston Infectious Diseases Institute (HeIDI), Metro North Health (particularly Chapter 20)
- Associate Professor Owen Robinson – Infectious Diseases Physician, Royal Perth Hospital
- Dr Chris Robson – Infectious Diseases and Hospital In The Home Physician, Monash Health (particularly Chapter 20)
- Associate Professor Benjamin A Rogers – Infection Disease & HITH Physician, Monash Health (particularly Chapter 20)
- Professor Debra Rowett – PSM, University of South Australia & Southern Adelaide Local Health Network (particularly Chapter 16)
- Dr Kelly Shaw – KP Health (particularly Chapters 13, 14, 15, 16, 17, 18, 19 and 20)
- Dr Fekade B. Sime – NHMRC Emerging Leadership Fellow, The University of Queensland Centre for Clinical Research, Brisbane, QLD (particularly Chapter 20)
- Ms Vanessa Simpson – NPS MedicineWise
- Ms Carrie Spinks – Infection Control Specialist, arcare (particularly Chapter 16)
- Dr Andrew Staib – Emergency Medicine, Princess Alexandra Hospital
- Mr Mike Stephens – Director, Medicines Policy and Programs at National Aboriginal Community Controlled Health Organisation (particularly Chapter 15)
- Ms Michelle Stirling – Infection Control Specialist, Hall & Prior (particularly Chapter 16)
- Dr Clair Sullivan – Consultant Endocrinologist and Medical Informatician, Princess Alexandra Hospital
- Dr Leanne Teoh, NCAS Dentist and Pharmacist (particularly Chapter 18)
- Mr Horst Thiele – Senior pharmacist Hospital in the Home (HITH) Northern Sydney Local Health District (particularly Chapter 20)
- Mr Murray Thomas, Chair, Dental Board of Australia (particularly Chapter 18)
- Dr Wendy Thompson, academic general dental practitioner, University of Manchester (particularly Chapter 18)
- Ms Susan Trevillian, Deputy Director of Pharmacy, Northeast Health Wangaratta, VIC (particularly Chapter 17)
- Dr Danny Tsai – Antimicrobial Stewardship Pharmacist at the Alice Springs Hospital (particularly Chapters 15 and 17)
- Dr Lydia Upjohn –Infectious Diseases Physician, Monash Health (particularly Chapter 20)
- Glenn Valoppi – AMS Pharmacist, Slade Pharmacy, Vic (particularly Chapter 19)
- Dr Caitlyn White – Kimberley Aboriginal Medical Services, Broome (particularly Chapter 15)
- Dr Helena Williams – Chair, ACSQHC Primary Care Committee (particularly Chapter 13)
- Dr Amalie Wilke – Infectious Diseases specialist, Cabrini Health, Vic (particularly Chapter 19)
- Dr Helena Williams – Chair, ACSQHC Primary Care Committee (particularly Chapter 13)

- Dr Amalie Wilke – Infectious Diseases specialist, Cabrini Health, Vic (particularly Chapter 19)
- Dr Paul Woodhouse – KP Health (particularly Chapter 20)
- Dr Melanie Wroth – Geriatrician, Chief Clinical Advisor - Aged Care Quality and Safety Commission (ACSQC)
- Dr Paul Yates – Consultant Geriatrician, Medical Lead, Residential Inreach Service, Austin Health (particularly Chapter 16)
- Dr Sue-Ching Yeoh, Chair, Federal Dental Therapeutics Committee (particularly Chapter 18)
- Ms Sharon Young – Sunshine Coast Hospital and Health Service (particularly Chapter 16).

Commission staff were also involved in the writing and review of this publication, and the Commission wishes to acknowledge:

- Ms Margaret Banks
- Ms Debbie Carter
- Professor Marilyn Cruickshank
- Ms Fiona Doukas
- Dr Nicola Dunbar
- Conjoint Professor Anne Duggan
- Ms Nilva Egana
- Ms Lisa Harris
- Dr Robert Herkes
- Conjoint Associate Professor Carolyn Hullick
- Ms Eliza McEwin
- Adjunct Professor Kathy Meleady PSM
- Adjunct Professor Debora Picone AO
- Ms Naomi Poole
- Ms Kim Stewart
- Ms Lucia Tapsall
- Mr Michael Wallace

- Ms Kristin Xenos

The following Commission Committees are thanked for their involvement in their review.

- Aboriginal and Torres Strait Islander Health Advisory Group (particularly Chapter 15)
- Antimicrobial Stewardship Advisory Committee (all Chapters)
- Healthcare-Associated Infection Advisory Committee (all Chapters)

The following external Committees were also involved in the review.

- Australian and New Zealand Society for Geriatric Medicine (ANZSGM) – Clinical Issues Committee (particularly Chapter 16)

In addition, the Commission wishes to acknowledge the members of the Society of Hospital Pharmacists of Australia Infectious Diseases Committee of Specialty Practice for their contribution in reviewing this publication; and the staff of Biotext for their expert review, editing and design services (Chapters 1 – 12).

Please note that there have been progressive additions to this publication since 2018:

- 2018 Chapters 1–12
- 2020 Chapters 13–14
- 2021 Chapters 15–17
- 2022 Chapter 18
- 2022 Chapter 19
- 2023 Chapter 20

The titles and affiliations of contributors may have changed since the time that they contributed this publication.

# Contents

<b>Summary</b> .....	<b>1</b>
<b>Key issues</b> .....	<b>3</b>
The challenge .....	3
The response .....	3
Australian framework for AMS .....	3
Essential elements of antimicrobial stewardship .....	3
<b>This publication</b> .....	<b>4</b>
Aim.....	4
Structure.....	4
<b>Chapter 1: Evidence for antimicrobial stewardship</b> .....	<b>7</b>
Acronyms and abbreviations.....	10
1.1 Introduction.....	11
1.2 Challenge and impact of antimicrobial resistance .....	12
1.2.1 Association between antimicrobial use and resistance .....	12
1.2.2 Consequences of antimicrobial resistance .....	13
1.3 Australian framework for antimicrobial stewardship .....	14
1.3.1 National standards and guidelines .....	14
1.3.2 National Antimicrobial Resistance Strategy .....	17
1.3.3 Antimicrobial stewardship in the states and territories .....	17
1.3.4 Therapeutic Guidelines .....	17
1.3.5 Surveillance of antimicrobial use and resistance in Australia .....	18
1.3.6 Education and awareness raising .....	19
1.3.7 Antimicrobial stewardship research .....	20
1.3.8 Professional societies and organisations .....	20
1.4 Antimicrobial use .....	21
1.4.1 Factors contributing to unnecessary and inappropriate antimicrobial use .....	21
1.4.2 Antimicrobial use in Australia .....	21
1.4.3 Harmful effects of antimicrobial use .....	21
1.5 Antimicrobial stewardship .....	22
1.5.1 Effective antimicrobial stewardship .....	22
1.5.2 Evidence to support the benefits of antimicrobial stewardship .....	24
1.5.3 Unintended consequences of antimicrobial stewardship programs .....	27
References .....	29
Appendix A: Examples of antimicrobial stewardship (AMS) activities and resources in Australian states and territories .....	34

<b>Chapter 2: Establishing and sustaining an antimicrobial stewardship program</b>	<b>35</b>
Acronyms and abbreviations .....	38
2.1 Introduction .....	39
2.2 Essential elements of antimicrobial stewardship programs .....	40
2.3 Structure and governance .....	41
2.3.1 Safety and quality improvement .....	41
2.3.2 Governance .....	41
2.3.3 Executive leadership .....	44
2.3.4 Clinical leadership .....	44
2.4 Antimicrobial stewardship committee and team .....	45
2.4.1 Antimicrobial stewardship committee .....	45
2.4.2 Antimicrobial stewardship team .....	48
2.5 Antimicrobial stewardship program plan .....	49
2.5.1 Assessing readiness to implement an antimicrobial stewardship program or intervention .....	49
2.5.2 Reviewing existing policies and prescribing guidelines .....	53
2.5.3 Reviewing local data on antimicrobial use and resistance .....	55
2.5.4 Determining priority areas for antimicrobial stewardship activities .....	56
2.5.5 Identifying effective interventions .....	57
2.5.6 Defining measurable goals and outcomes .....	58
2.5.7 Documenting and implementing the antimicrobial stewardship plan .....	59
2.5.8 Educating the workforce .....	59
2.5.9 Developing and implementing a communication plan .....	60
2.6 Sustaining the antimicrobial stewardship program .....	60
Resources .....	61
References .....	63
Appendix A: Examples of successful and sustained antimicrobial stewardship programs .....	66
<b>Chapter 3: Strategies and tools for antimicrobial stewardship</b> .....	<b>75</b>
Acronyms and abbreviations .....	78
3.1 Introduction .....	79
3.2 Prescribing guidelines .....	81
3.2.1 National guidelines .....	81
3.2.2 Local guidelines .....	81
3.2.3 Promoting guideline uptake .....	82
3.2.4 Tools and resources to support guideline implementation .....	82
3.2.5 Education and feedback .....	83
3.2.6 Antimicrobial stewardship care bundles .....	83
3.3 Formularies and approval systems .....	83
3.3.1 National formulary .....	83
3.3.2 State and territory formularies .....	84
3.3.3 Hospital formularies .....	84
3.3.4 Antimicrobial approval systems .....	85



3.4 Post-prescription reviews .....	87
3.4.1 Who should perform reviews in hospitals? .....	87
3.4.2 Which patients should be reviewed? .....	89
3.4.3 What should be included in the feedback? .....	89
3.4.4 How should feedback be provided? .....	89
3.4.5 Prescription review at transitions of care .....	90
3.4.6 Post-prescription reviews in the community setting .....	90
3.5 Point-of-care interventions .....	91
3.5.1 Directing therapy based on results from microscopy and other rapid tests .....	91
3.5.2 Directing therapy based on culture and susceptibility test results .....	91
3.5.3 Optimising dosing .....	91
3.5.4 Limiting toxicity .....	92
3.5.6 Changing the duration of therapy .....	92
3.5.7 Switching from intravenous to oral delivery .....	92
3.5.8 Escalating to formal expert clinical review .....	93
Resources .....	94
References .....	95
<b>Chapter 4: Information technology to support antimicrobial stewardship.....</b>	<b>99</b>
Acronyms and abbreviations .....	102
4.1 Introduction .....	103
4.2 Electronic clinical decision support systems .....	104
4.2.1 Passive decision support systems and smartphone apps .....	105
4.2.2 Electronic approval systems .....	108
4.2.3 Electronic surveillance and infection prevention systems .....	109
4.2.4 Electronic prescribing and medication management systems .....	110
4.2.5 Advanced decision support systems .....	111
4.2.6 Implementing electronic clinical decision support systems for antimicrobial stewardship .....	112
4.2.7 Electronic clinical decision support in primary care .....	113
4.3 Data collection and reporting .....	114
4.4 Telehealth .....	115
Resources .....	117
References .....	118
<b>Chapter 5: Antimicrobial stewardship education for clinicians .....</b>	<b>123</b>
Acronyms and abbreviations .....	126
5.1 Introduction .....	127
5.2 Key elements of antimicrobial stewardship education .....	128
5.2.1 Audiences .....	128
5.2.2 Principles of education on antimicrobial stewardship .....	129
5.2.3 Antimicrobial stewardship competencies and standards .....	129
5.2.4 Influence of the pharmaceutical industry .....	131
5.2.5 Evaluation of educational activities .....	132

5.3 Antimicrobial stewardship education for different groups and stages .....	132
5.3.1 Undergraduate training .....	132
5.3.2 Early-career development .....	133
5.3.3 Continuing education and professional development .....	134
5.3.4 Education and training for antimicrobial stewardship teams .....	136
5.3.5 Specialist training .....	137
5.4 Education resources .....	137
5.4.1 Guidelines .....	137
5.4.2 Websites and online learning resources .....	137
5.4.3 Educators .....	138
Resources .....	139
References .....	140
Appendix A: Managing conflicts of interest and relationships with the pharmaceutical industry – further reading and links .....	143
Appendix B: Example of a ‘Did you know’ email for clinicians .....	144
<b>Chapter 6: Measuring performance and evaluating antimicrobial stewardship programs .....</b>	<b>147</b>
Acronyms and abbreviations .....	150
6.1 Introduction .....	151
6.2 Key elements of antimicrobial stewardship measurement .....	152
6.2.1 What should be measured? .....	152
6.2.2 Measurement approaches .....	152
6.3 Structure measures .....	152
6.3.1 Hospitals .....	152
6.3.2 Community .....	154
6.4 Process measures .....	154
6.5 Outcome measures .....	155
6.5.1 Improved patient outcomes .....	156
6.5.2 Improved patient safety .....	156
6.5.3 Reduced resistance .....	156
6.5.4 Reduced costs .....	157
6.5.5 Qualitative and other related measures of program activity .....	157
6.6 Balancing measures .....	157
6.7 Surveillance of antimicrobial use .....	158
6.7.1 Measuring the volume of antimicrobial use in hospitals .....	158
6.7.2 Measuring the volume of antimicrobial use in the community .....	160
6.7.3 Reporting and monitoring use data at the local level .....	161
6.8 Auditing the quality of antimicrobial prescribing .....	164
6.8.1 Auditing prescribing in hospitals .....	164
6.8.2 Auditing prescribing in the community .....	166
6.8.3 Quality improvement audits .....	167

6.9 Reporting, feedback and use of data .....	168
6.9.1 Health service organisation reports .....	168
6.9.2 State and territory reports .....	168
6.9.3 National reports .....	168
6.9.4 Use of data for benchmarking .....	169
Resources .....	171
References .....	172
<b>Chapter 7: Involving consumers in antimicrobial stewardship .....</b>	<b>177</b>
Acronyms and abbreviations .....	180
7.1 Introduction .....	181
7.2 Consumer awareness and expectations .....	182
7.2.1 Consumer understanding of when antimicrobials are needed .....	182
7.2.2 Consumer awareness and understanding of antimicrobial resistance .....	182
7.2.3 Previous experience of antimicrobials .....	183
7.3 Key messages and communication .....	183
7.3.1 Reassurance .....	183
7.3.2 Health literacy .....	183
7.3.3 Communication with consumers in different settings and circumstances .....	185
7.4 Consumer resources and tools .....	186
7.4.1 Before the consultation .....	186
7.4.2 During the consultation .....	187
7.4.3 After the consultation .....	188
7.4.4 Reaching and engaging consumers nationally .....	188
7.4.5 Antibiotic Awareness Week .....	190
Resources .....	191
References .....	192
<b>Chapter 8: Role of the infectious diseases service in antimicrobial stewardship .....</b>	<b>195</b>
Acronyms and abbreviations .....	198
8.1 Introduction .....	199
8.2 Leadership .....	199
8.2.1 Participating in the antimicrobial stewardship team and committees .....	200
8.2.2 Implementing and maintaining antimicrobial policies and guidelines .....	201
8.3 Expert advice .....	201
8.3.1 Specific situations requiring infectious diseases physician expertise .....	202
8.3.2 Support for external organisations .....	203
8.4 Support for formularies and approval systems .....	204
8.4.1 Formularies .....	204
8.4.2 Approval systems .....	204
8.5 Prescription review with feedback .....	205
8.5.1 Antimicrobial stewardship team rounds .....	205
8.5.2 Conflicting advice .....	205

8.6 Monitoring antimicrobial use and evaluating interventions .....	206
8.7 Liaison .....	207
8.7.1 Liaison within hospitals .....	207
8.7.2 Interacting with the pharmaceutical industry .....	207
8.8 Role in education .....	208
Resources .....	209
References .....	209
<b>Chapter 9: Role of the clinical microbiology service in antimicrobial stewardship .....</b>	<b>213</b>
Acronyms and abbreviations .....	216
9.1 Introduction .....	217
9.2 Overview of the diagnostic testing process .....	217
9.3 Pre-analytical phase: microbiology process .....	218
9.3.1 Selecting diagnostic tests .....	218
9.3.2 Collecting and transporting samples .....	220
9.3.3 Commenting on specimen quality .....	221
9.4 Analytical phase: microbiological analytical practice .....	221
9.4.1 Rapid diagnostics and testing .....	221
9.4.2 Antimicrobial susceptibility testing .....	222
9.5 Post-analytical phase: microbiology reporting .....	222
9.5.1 Timeliness of reporting and integration with antimicrobial stewardship programs ...	222
9.5.2 Reporting and interpreting results .....	222
9.5.3 Cascade reporting .....	224
9.5.4 Communicating critical results .....	225
9.6 Specific situations that need clinical microbiology service expertise .....	225
9.6.1 Support for high-risk units .....	225
9.6.2 Cumulative antibiogram analysis .....	226
9.6.3 Signal and critical antimicrobial resistances (CARs) .....	226
9.6.4 Therapeutic drug monitoring and review .....	228
9.6.5 Linking microbiology results with electronic prescribing .....	228
9.6.6 Measuring performance of the clinical microbiology service as part of the antimicrobial stewardship program .....	228
9.7 Role in education .....	229
Resources .....	230
References .....	231
<b>Chapter 10: Role of prescribers in antimicrobial stewardship .....</b>	<b>237</b>
Acronyms and abbreviations .....	240
10.1 Introduction .....	241
10.2 Prescriber concerns and influences .....	242
10.2.1 Prescriber perspectives on antimicrobial resistance .....	242
10.2.2 Policies and guidelines .....	242
10.2.3 Diagnostic uncertainty .....	243

10.2.4 Influence of others .....	243
10.2.5 Prescribers in aged care .....	244
10.2.6 Non-medical prescribers .....	244
10.3 Prescriber strategies .....	245
10.3.1 Antimicrobial stewardship prescribing principles .....	245
10.3.2 Prescribing in specific situations .....	246
10.4 Prescriber resources and tools .....	247
10.4.1 Guidelines and antimicrobial information .....	247
10.4.2 Antimicrobial Stewardship Clinical Care Standard .....	247
10.4.3 Education and professional development .....	247
Resources .....	248
References .....	249
<b>Chapter 11: Role of the pharmacist and pharmacy services in antimicrobial stewardship .....</b>	<b>253</b>
Acronyms and abbreviations .....	256
11.1 Introduction .....	257
11.2 Pharmacists and antimicrobial stewardship .....	257
11.2.1 Activities in different settings .....	258
11.2.2 Pharmacy managers .....	261
11.2.3 Roles of antimicrobial stewardship pharmacists .....	262
11.3 Leadership .....	262
11.3.1 Promoting uptake and compliance with national standards for antimicrobial stewardship .....	263
11.3.2 Developing and maintaining antimicrobial guidelines .....	263
11.4 Expert advice .....	263
11.4.1 Providing expert advice to clinicians, patients and carers .....	263
11.4.2 Participating in antimicrobial stewardship ward rounds .....	263
11.4.3 Initiating point-of-care interventions .....	264
11.5 Formularies and approval systems .....	264
11.6 Monitoring antimicrobial use and evaluating interventions .....	264
11.7 Liaison .....	265
11.8 Education .....	265
11.8.1 Antimicrobial stewardship education for pharmacists .....	265
11.8.2 Pharmacists' role in education .....	267
Resources .....	268
References .....	269
Appendix A: Examples of training and educational opportunities for AMS pharmacists .....	271

<b>Chapter 12: Role of nurses, midwives and infection control practitioners in antimicrobial stewardship</b> .....	<b>273</b>
Acronyms and abbreviations.....	276
12.1 Introduction.....	277
12.2 Nursing and midwifery practice and antimicrobial stewardship .....	277
12.3 Facilitating nursing and midwifery involvement .....	280
12.3.1 Planning for nursing and midwifery involvement .....	280
12.3.2 Promoting a safety culture .....	282
12.3.3 Education.....	283
12.3.4 Resources and tools.....	284
12.4 Advanced and specialist practice roles.....	285
12.4.1 Nurse practitioners.....	285
12.4.2 Infection control practitioners .....	286
Resources .....	289
References.....	290
<b>Chapter 13: Role of general practice in antimicrobial stewardship</b> .....	<b>293</b>
Acronyms and abbreviations.....	296
13.1 Introduction .....	297
13.1.1 Antimicrobial resistance in the community .....	298
13.1.2 Antimicrobial use in the community .....	298
13.1.3 Antimicrobial use and general practice .....	299
13.2 Factors that influence antimicrobial prescribing in general practice.....	299
13.2.1 General practice characteristics .....	299
13.2.2 Patient characteristics .....	300
13.2.3 Indigenous populations .....	300
13.2.4 Residential aged care facilities .....	300
13.2.5 Patient expectations .....	300
13.2.6 Diagnostic uncertainty .....	301
13.3 Antimicrobial stewardship strategies for general practice .....	301
13.3.1 Before the consultation .....	302
13.3.2 During the consultation .....	303
13.3.2 After the consultation .....	304
13.4 Clinical governance and leadership for antimicrobial stewardship .....	307
13.4.1 Professional leadership .....	307
13.4.2 National leadership .....	307
13.4.3 Regional leadership.....	307
13.4.4 Practice leadership .....	307
Resources .....	308
References .....	309
<b>Chapter 14: Antimicrobial stewardship in the care of children</b> .....	<b>313</b>
Acronyms and Abbreviations .....	316
Key Points .....	317

14.1 Introduction.....	318
14.1.1 Antimicrobial use in children.....	318
14.1.2 Antimicrobial resistance and children.....	319
14.1.3 Antimicrobial stewardship in paediatric care.....	319
14.2 Factors that influence antimicrobial prescribing in children.....	320
14.2.1 Anatomical and physiological factors.....	320
14.2.2 Antimicrobial access and safety factors.....	320
14.2.3 Other factors.....	321
14.3 Antimicrobial Stewardship strategies for paediatric Care.....	322
14.3.1 Reduce antimicrobial prescribing in primary care.....	322
14.3.2 Limit duration of antimicrobial therapy.....	323
14.3.3 Intravenous to oral switch.....	324
14.3.4 Antimicrobial dose optimisation.....	325
14.3.5 Rapid diagnostics.....	325
14.4 Implementing and leading antimicrobial stewardship in paediatric care.....	325
14.4.1 A team approach to AMS.....	325
14.4.2 Plans and strategies for AMS programs.....	326
14.4.3 Targeted approaches.....	327
14.4.4 Education.....	327
14.5 Measuring AMS performance.....	328
14.5.1 Rate of antimicrobial use.....	328
14.5.2 Appropriateness of use.....	328
14.5.3 Outcome measures.....	329
Resources.....	330
References.....	332
<b>Chapter 15: Antimicrobial stewardship in the Aboriginal and Torres Strait Islander population ..</b>	<b>339</b>
Acronyms and abbreviations.....	342
Key points.....	343
15.1 Introduction.....	344
15.1.1 Aboriginal and Torres Strait Islander demographic characteristics.....	344
15.1.2 Infectious diseases and Aboriginal and Torres Strait Islander peoples.....	344
15.2 Antimicrobial use.....	345
15.2.1 Impact of vaccination on antimicrobial use.....	346
15.2.2 Antimicrobial resistance.....	347
15.3 Antimicrobial stewardship.....	347
15.3.1 Social determinants of health and infectious diseases.....	347
15.3.2 Cultural considerations in antimicrobial stewardship.....	350
15.4 Antimicrobial stewardship and Aboriginal Community Controlled Health Organisations.....	351
15.4.1 Establishing Aboriginal Community Controlled Health Organisation antimicrobial stewardship programs.....	352
15.4.2 Community development.....	353
15.4.3 Governance.....	353
15.4.4 Standards, policies and guidelines.....	353

15.4.5 The antimicrobial stewardship team.....	354
15.4.6 Antimicrobial stewardship program strategies.....	354
15.4.7 Prescribing guidelines.....	354
15.4.8 Antimicrobial formulary .....	354
15.4.9 Monitoring of antimicrobial use and evaluation of the antimicrobial stewardship program .....	354
15.4.10 Surveillance of antimicrobial resistance and antibiograms .....	354
15.4.11 Audit and feedback.....	355
15.4.12 Staff education .....	355
15.4.13 Community and patient education .....	355
<b>15.5 Conclusions.....</b>	<b>356</b>
<b>Resources .....</b>	<b>357</b>
<b>References.....</b>	<b>358</b>
<b>Chapter 16: Antimicrobial stewardship in community and residential aged care .....</b>	<b>363</b>
<b>Acronyms and Abbreviations .....</b>	<b>366</b>
<b>Key Points .....</b>	<b>367</b>
<b>16.1 Introduction.....</b>	<b>368</b>
16.1.1 Aged care services in Australia.....	368
16.1.2 Infectious disease and ageing.....	368
16.1.3 Presentation of infections in older people.....	369
16.1.4 Infectious diseases and aged care services .....	369
<b>16.2 Antimicrobial use and aged care services .....</b>	<b>369</b>
16.2.1 Antimicrobial resistance .....	372
<b>16.3 Antimicrobial stewardship.....</b>	<b>373</b>
<b>16.4 Antimicrobial stewardship program strategies .....</b>	<b>373</b>
16.4.1 Program governance .....	373
16.4.2 The AMS team .....	373
16.4.3 Policies and prescribing guidelines.....	374
16.4.4 Monitoring and surveillance.....	379
16.4.5 Audit and feedback.....	381
16.4.6 Education and training .....	382
16.4.7 Preventing and managing infections.....	382
<b>16.5 Conclusions.....</b>	<b>385</b>
<b>Resources .....</b>	<b>386</b>
<b>References.....</b>	<b>388</b>
<b>Chapter 17: Rural and remote hospitals and health services .....</b>	<b>391</b>
<b>Acronyms and Abbreviations .....</b>	<b>394</b>
<b>Key Points .....</b>	<b>395</b>
<b>17.1 Introduction.....</b>	<b>396</b>
17.1.1 Factors impacting AMS in rural and remote hospitals .....	396



17.2 Establishing AMS in rural and remote hospitals.....	398
17.2.1 Governance .....	398
17.2.2 Local AMS Committee and team.....	399
17.2.3 Expect advice and support .....	400
17.3 Antimicrobial stewardship strategies in rural and remote hospitals .....	402
17.3.1 Antimicrobial prescribing policy.....	402
17.3.2 Prescribing guidelines and structured care bundles .....	403
17.3.3 Formulary restrictions and approval systems .....	404
17.3.4 Prescription review and feedback.....	404
17.3.5 Monitoring and reporting antimicrobial use and resistance.....	405
17.3.6 Evaluating program outcomes .....	407
17.3.7 Education.....	408
17.4 Enablers for AMS in rural and remote hospitals .....	408
17.4.1 Clinical team support.....	408
17.4.2 Digital support.....	410
17.5 Conclusions.....	411
Resources .....	412
References.....	414
<b>Chapter 18: Dental practice .....</b>	<b>419</b>
Acronyms and Abbreviations .....	422
Key Points .....	423
18.1 Introduction.....	424
18.1.1 Association between antimicrobial use and resistance .....	424
18.2 Antimicrobial prescribing in dental practice .....	424
18.2.1 Indications for prescribing of antimicrobials in dental practice.....	425
18.2.2 Overuse of antimicrobials in managing odontogenic complaints.....	426
18.2.3 Factors that influence antimicrobial prescribing in dental practice.....	427
18.3 Antimicrobial stewardship strategies in dental practice.....	428
18.3.1 Understanding the context and identifying priorities.....	428
18.3.2 Interventions to support antimicrobial stewardship .....	430
18.3.3 Monitoring the outcomes of antimicrobial stewardship activities.....	430
18.4 Clinical governance and leadership.....	430
18.5 Conclusion .....	431
Resources .....	432
References.....	433
<b>Chapter 19: Private hospitals .....</b>	<b>435</b>
Acronyms and Abbreviations .....	438
Key Points .....	439
19.1 Introduction.....	440
19.1.1 Private hospital care.....	440
19.1.2 Antimicrobial use and private hospitals.....	441
19.2 Establishing antimicrobial stewardship in private hospitals .....	441
19.2.1 Antimicrobial stewardship governance in private hospitals .....	441
19.2.2 The private hospital antimicrobial stewardship committee and team.....	442

19.2.3 Obtaining private hospital clinical buy-in.....	443
19.2.4 Obtaining expert antimicrobial stewardship advice and support in private hospitals .....	443
19.2.5 Assessing the current antimicrobial stewardship program in private hospitals .....	443
<b>19.3 Antimicrobial stewardship strategies in private hospitals .....</b>	<b>443</b>
19.3.1 Antimicrobial prescribing policies in private hospitals.....	444
19.3.2 Formulary restrictions and approval systems in private hospitals.....	444
19.3.3 Implementing prescribing guidelines and structured care bundles in private hospitals .....	444
19.3.4 Prescription review and feedback in private hospitals .....	445
19.3.5 Monitoring and reporting antimicrobials use and resistance .....	445
19.3.6 Measuring antimicrobial stewardship program performance and outcomes .....	445
19.3.7 Clinician education in private hospitals.....	446
<b>19.4 Conclusions.....</b>	<b>446</b>
<b>Resources .....</b>	<b>448</b>
<b>References.....</b>	<b>449</b>
<b>Chapter 20: Antimicrobial Stewardship and Outpatient Parenteral Antimicrobial Therapy in Hospital in the Home and other settings .....</b>	<b>451</b>
<b>Acronyms and Abbreviations .....</b>	<b>454</b>
<b>Key Points .....</b>	<b>455</b>
<b>20.1 Introduction.....</b>	<b>456</b>
20.1.1 OPAT and HITH .....	456
<b>20.2 Outpatient parenteral antimicrobial therapy.....</b>	<b>457</b>
20.2.1 Governance for OPAT service delivery .....	457
20.2.2 Integration of antimicrobial stewardship into OPAT services.....	457
<b>20.3 Antimicrobial stewardship and OPAT services .....</b>	<b>458</b>
20.3.1 The OPAT multidisciplinary team .....	458
20.3.2 Clinical leadership.....	458
20.3.3 Patient selection.....	458
20.3.4 Patient Education .....	459
20.3.5 Antimicrobial selection.....	459
20.3.6 Antimicrobial administration.....	460
20.3.7 De-escalation of therapy - intravenous to oral antimicrobial switch (IVOST).....	461
20.3.8 Transition of care from OPAT and HITH .....	461
20.3.9 Telemedicine and HITH .....	461
<b>20.4 Outcomes monitoring and reporting .....</b>	<b>461</b>
20.4.1 Patient experience at the completion of care.....	462
<b>20.5 Conclusions.....</b>	<b>465</b>
<b>Resources .....</b>	<b>466</b>
<b>References.....</b>	<b>468</b>
<b>Glossary .....</b>	<b>G1-G11</b>